EL PASO, Texas -- (BUSINESS WIRE) -- Premier Biomedical Inc. (OTCBB: BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer’s disease, multiple sclerosis (“MS”), and traumatic brain injury (“TBI”), today announced the release of a market study conducted by Penn Biotech Group Healthcare Consulting (“PBG”) discussing its breast cancer treatment.
“We commissioned Penn Biotech Group (PBG) to evaluate strategies to take our anti-CTLA4 breast cancer treatment through FDA approval,” said President & CEO William Hartman. “After an exhaustive analysis, including 450 hours of pro-bono work interviewing oncologists and reviewing medical literature, the group projected that our treatment could achieve annual revenue of up to $1.9 billion.”
Investors can download the complete study in PDF format here: http://www.premierbiomedical.com/PBGAbridgedReport.pdf
Anti-CTLA4 has become widely popular following the FDA approval of Bristol-Myers Squibb’s Yervoy in 2011 for the treatment of inoperable metastatic melanoma. By targeting the CTLA4 protein receptor responsible for down-regulating the immune system, the monoclonal antibody re-enables T-cells and immune system. Versions of the drug are undergoing clinical trials in lung, bladder, and prostate cancers as well.
About PBG Healthcare Consulting
Penn Biotech Group Healthcare Consulting (PBG) is a cross-disciplinary student run organization at the University of Pennsylvania. PBG focuses on addressing the challenges and obstacles facing the biotechnology industry today. To this end, PBG provides members with education, real-world experience and networking opportunities to enrich their exposure within the biotechnology arena. Visit PBG’s website at www.pbgconsulting.org.
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, in collaboration with the University of Texas at El Paso and US Department of Defense, specifically targeting the treatment of Alzheimer's disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX and their business offices are in Western Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI."http://www.premierbiomedicalinc.com/
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.